Indoleamine 2,3-dioxygenase vaccination.

• 发表时间: Jan 2015
• 来源期刊: Oncoimmunology
• DOI: 10.4161/2162402X.2014.983770
• PMID: 25949864
• 文章类型: Journal Article
• 中科院分区: Q2
• 方向: 医学
• 作者列表: Andersen MH,Svane IM

关键词: CD8; DC, dendritic cells; IDO; IDO, indoleamine 2,3-dioxygenase; NSCLC; NSCLC, non-small-cell lung cancer; OS, overall survival; PBMC, peripheral blood mononuclear cells; PD, progressive disease; PD-L1; SD, stable disease; Tregs, regulatory T cells; cancer vaccine

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.